Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $1.7 billion.

  • Genmab A's Cash & Equivalents fell 2218.69% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year decrease of 2218.69%. This contributed to the annual value of $1.7 billion for FY2025, which is 2218.69% down from last year.
  • According to the latest figures from Q4 2025, Genmab A's Cash & Equivalents is $1.7 billion, which was down 2218.69% from $1.8 billion recorded in Q3 2025.
  • In the past 5 years, Genmab A's Cash & Equivalents registered a high of $2.2 billion during Q4 2023, and its lowest value of $622.0 million during Q2 2024.
  • In the last 3 years, Genmab A's Cash & Equivalents had a median value of $1.7 billion in 2025 and averaged $1.6 billion.
  • Data for Genmab A's Cash & Equivalents shows a peak YoY increase of 10836.01% (in 2025) and a maximum YoY decrease of 2388.34% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Genmab A's Cash & Equivalents stood at $2.2 billion in 2023, then changed by 0.0% to $2.2 billion in 2024, then decreased by 22.19% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q4 2025, $1.8 billion for Q3 2025, and $1.3 billion during Q2 2025.